Recruiting

Number
Title
Target
accrual
EORTC Brain Tumor Group
22042
26042
Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma : a Phase II and observation study

Study Coordinator:

Damien Weber, Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie, Geneve

54
26053
22054
Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON intergroup trial.

Study Coordinators:

Brigitta Baumert, MediClin Robert Janker Klinik, Bonn

Martin J. van den Bent, Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam

748
26062
22061
A randomized phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients

Study Coordinator:

Alba Brandes, Ospedale Bellaria, Bologna

560
26091
TAVAREC
Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial.

Study Coordinator:

Martin J. van den Bent, Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam

144
26101
Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.

Study Coordinator:

Wolfgang Wick, Universitaetsklinikum Heidelberg - UniversitaetsKlinikum Heidelberg - Head Hospital, Heidelberg

249
EORTC Breast Cancer Group
10085
Male BC
Clinical and biological characterization of Male Breast Cancer : an international retrospective EORTC, BIG and NABCG intergroup study.

Study Coordinators:

Fatima Cardoso, Champalimaud Cancer Center, Lisboa

Sharon Hermes Giordano, Md Anderson Cancer Center, Houston

1800
10112
Aphinity
A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer.

Study Coordinator:

Fatima Cardoso, Champalimaud Cancer Center, Lisboa

3806
22085
10083
A randomized phase III study of radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast.

Study Coordinator:

Helen Westenberg, Arnhem's Radiotherapeutisch Instituut, Arnhem

610
90091
10093
TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) ("Treat CTC" trial)

Study Coordinator:

Michail Ignatiadis, Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels

250
EORTC Cancer in Elderly Task Force
40085
75083
Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geriatric Assessment.

Study Coordinator:

Marc Peeters, Universitair Ziekenhuis Antwerpen, Edegem

150
EORTC Children's Leukemia Group
58051
Interfant
International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia

Study Coordinator:

Alina Ferster, Hopital Universitaire Des Enfants Reine Fabiola, Brussels

445
58081
Translational research - observational study for identification of new possible prognostic factors and future therapeutic targets in children with acute lymphoblastic leukaemia (ALL).

Study Coordinator:

Helene Cave, Assistance Publique - Hôpitaux de Paris - Hopital Robert Debre AP-HP, Paris

800
58LAE
Assessment of the long term outcome of childhood ALL patients enrolled in EORTC CLG trials between 1971 and 1998

Study Coordinator:

Caroline Piette, Centre Hospitalier Regional De La Citadelle, Liege

3138
EORTC Gastrointestinal Tract Cancer Group
40071
Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction, metastatic or not amenable to curative surgery according to HER2 and EGFR status: a randomized phase II trial.

Study Coordinator:

Arnaud Roth, Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie, Geneve

192
40084
22084
A phase III trial evaluating both Erlotinib and Chemoradiation as adjuvant treatment for patients with resected head of pancreas adenocarcinoma

Study Coordinator:

Jean-Luc Van Laethem, Hôpitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme, Brussels

950
40085
75083
Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geriatric Assessment.

Study Coordinator:

Marc Peeters, Universitair Ziekenhuis Antwerpen, Edegem

150
40091
BOS 2
Randomized phase II trial evaluating the efficacy of FOLFOX alone, FOLFOX plus bevacizumab and FOLFOX plus panitumumab as perioperative treatment in patients with resectable liver metastases from wild type KRAS colorectal cancer

Study Coordinators:

Stephane Benoist, Assistance Publique - Hôpitaux de Paris - Hopital De Bicetre AP-HP, Le Kremlin Bicetre

Bernard Nordlinger, CHU Ambroise Pare AP-HP, Boulogne-Billancourt

360
40101
POWER
An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced or metastatic esophageal squamous cell cancer (ESCC)

Study Coordinator:

Baruch Brenner, Rabin Medical Center - Tel Aviv University, Petah Tiqva

300
EORTC Genito-Urinary Cancers Group
22043
30041
Immediate or early salvage post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus immediate or early salvage post-operative external radiotherapy alone in pT3a-b R0-1 cNOMO/pT2R1 cN0M0, Gleason score 5-10 prostatic carcinoma. A phase III study.

Study Coordinators:

Michel Bolla, CHU de Grenoble - La Tronche - Hôpital A. Michallon, Grenoble

Steven Joniau, U.Z. Leuven - Campus Gasthuisberg, Leuven

600
30073
SURTIME
Randomized Phase III trial comparing immediate versus deferred nephrectomy in patients with synchronous metastatic renal cell carcinoma.

Study Coordinators:

Axel Bex, The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam

John B.A.G. Haanen, The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam

458
EORTC Gynecological Cancer Group
55092
Phase IB-II, open label, multicentre feasibility study of Pazopanib in combination with Paclitaxel and Carboplatin in patients with platinum-refractory/resistant ovarian, fallopian tube or peritoneal carcinoma.

Study Coordinator:

Ignace Vergote, U.Z. Leuven - Campus Gasthuisberg, Leuven

36
55102
ENGOT-EN2-DGCG
A phase III Trial of postoperative chemotherapy or no further treatment for patients with stage I-II medium or high risk endometrial cancer.

Study Coordinators:

Frederic Amant, U.Z. Leuven - Campus Gasthuisberg, Leuven

Mansoor Raza Mirza, Rigshospitalet, Copenhagen

678
55994
Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa > 4 cm or IIb cervical cancer.

Study Coordinators:

Alessandro Colombo, Ospedale Alessandro Manzoni, Lecco

Gemma Kenter, Academisch Medisch Centrum - Universiteit van Amsterdam, Amsterdam

Fabio Landoni, Istituto Europeo Di Oncologia, Milano

686
EORTC Head and Neck Cancer Group
90111
24111
Neoadjuvant afatinib based treatment strategies followed by surgery in squamous cell carcinoma of the head and neck: an EORTC NOCI-HNCG window study

Study Coordinators:

Lisa Licitra, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Jean-Pascal Machiels, Cliniques Universitaires St. Luc, Brussels

30
EORTC Imaging Group
20101
23101
Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma (H11), a randomized phase III non-inferiority study of the EORTC Lymphoma Group and the Polish Lymphoma Research Group.

Study Coordinator:

Martin Hutchings, Rigshospitalet, Copenhagen

600
EORTC Infectious Diseases Group
65091
06093
Empirical versus pre-emptive (diagnostic-driven) antifungal therapy of patients treated for haematological malignancies or receiving an allogeneic stem cell transplant. A therapeutic open label phase III strategy study of the EORTC Infectious Diseases and Leukemia Groups

Study Coordinator:

Peter Donnelly, Radboud University Nijmegen Medical Centre, Nijmegen

556
EORTC Leukemia Group
06083
HOVON 100 ALL
Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults. A prospective randomized trial.

Study Coordinator:

Jean-Pierre Marie, Assistance Publique - Hôpitaux de Paris - Hopital Saint Antoine AP-HP, Paris

65091
06093
Empirical versus pre-emptive (diagnostic-driven) antifungal therapy of patients treated for haematological malignancies or receiving an allogeneic stem cell transplant. A therapeutic open label phase III strategy study of the EORTC Infectious Diseases and Leukemia Groups

Study Coordinator:

Peter Donnelly, Radboud University Nijmegen Medical Centre, Nijmegen

556
EORTC Lung Cancer Group
08072
22074
Concurrent once-daily versus twice-daily radiotherapy : A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status

Study Coordinator:

Corinne Faivre-Finn, Christie NHS Foundation Trust, Manchester

532
08092
MAPPING
Double blind randomized phase III study of maintenance Pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy.

Study Coordinator:

Mary O'Brien, Royal Marsden Hospital - Sutton, Surrey, Sutton

587
22055
08053
Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement - LUNG-ART

Study Coordinator:

Cecile Le Pechoux, Institut Gustave Roussy, Villejuif

700
EORTC Lymphoma Group
20101
23101
Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma (H11), a randomized phase III non-inferiority study of the EORTC Lymphoma Group and the Polish Lymphoma Research Group.

Study Coordinator:

Martin Hutchings, Rigshospitalet, Copenhagen

600
EORTC Melanoma Group
18081
Adjuvant peginterferon alpha-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group

Study Coordinator:

Alessandro Testori, Istituto Europeo Di Oncologia, Milano

1200
EORTC Network of Core Institutions
90091
10093
TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) ("Treat CTC" trial)

Study Coordinator:

Michail Ignatiadis, Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels

250
90101
CREATE
Cross-tumoral Phase 2 clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET ("CREATE")

Study Coordinator:

Patrick Schoeffski, U.Z. Leuven - Campus Gasthuisberg, Leuven

582
90111
24111
Neoadjuvant afatinib based treatment strategies followed by surgery in squamous cell carcinoma of the head and neck: an EORTC NOCI-HNCG window study

Study Coordinators:

Lisa Licitra, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Jean-Pascal Machiels, Cliniques Universitaires St. Luc, Brussels

30
EORTC Radiation Oncology Group
08072
22074
Concurrent once-daily versus twice-daily radiotherapy : A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status

Study Coordinator:

Corinne Faivre-Finn, Christie NHS Foundation Trust, Manchester

532
22042
26042
Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma : a Phase II and observation study

Study Coordinator:

Damien Weber, Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie, Geneve

54
22043
30041
Immediate or early salvage post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus immediate or early salvage post-operative external radiotherapy alone in pT3a-b R0-1 cNOMO/pT2R1 cN0M0, Gleason score 5-10 prostatic carcinoma. A phase III study.

Study Coordinators:

Michel Bolla, CHU de Grenoble - La Tronche - Hôpital A. Michallon, Grenoble

Steven Joniau, U.Z. Leuven - Campus Gasthuisberg, Leuven

600
22055
08053
Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement - LUNG-ART

Study Coordinator:

Cecile Le Pechoux, Institut Gustave Roussy, Villejuif

700
22085
10083
A randomized phase III study of radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast.

Study Coordinator:

Helen Westenberg, Arnhem's Radiotherapeutisch Instituut, Arnhem

610
26053
22054
Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON intergroup trial.

Study Coordinators:

Brigitta Baumert, MediClin Robert Janker Klinik, Bonn

Martin J. van den Bent, Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam

748
26062
22061
A randomized phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients

Study Coordinator:

Alba Brandes, Ospedale Bellaria, Bologna

560
40084
22084
A phase III trial evaluating both Erlotinib and Chemoradiation as adjuvant treatment for patients with resected head of pancreas adenocarcinoma

Study Coordinator:

Jean-Luc Van Laethem, Hôpitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme, Brussels

950
62092
22092
A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with Retroperitoneal sarcomas (RPS) - STRASS

Study Coordinator:

Sylvie Bonvalot, Institut Gustave Roussy, Villejuif

256
EORTC Soft Tissue and Bone Sarcoma Group
62092
22092
A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with Retroperitoneal sarcomas (RPS) - STRASS

Study Coordinator:

Sylvie Bonvalot, Institut Gustave Roussy, Villejuif

256

32 studies

19-Jun-13 12:17:36 AM